Although combination antiretroviral therapy has dramaticallyimproved the lives of patients with human immunodeficiency virus(HIV) infection, viral strains that are resistant to multiplemedications are a serious problem. Enfuvirtide, the new antiretroviralagent for patients with drug-resistant HIV infection, is noteworthyfor several reasons.
First, it works by a different mechanism from that of previousdrugs and heralds an era of new approaches to treatment. Enfuvirtide,which was initially known as T-20, inhibits the fusion of HIVtype 1 (HIV-1) with CD4+ cells. It does this by binding to aregion of the envelope that is involved in the . . . [Full Text of this Article]
This article has been cited by other articles:
Walker, A. R P, Walker, B. F, Wadee, A. A
(2005). A catastrophe in the 21st century: the public health situation in South Africa following HIV/AIDS. The Journal of the Royal Society for the Promotion of Health
125: 168-171
[Abstract]
Stebbing, J., Nelson, M., Orkin, C., Mandalia, S., Bower, M., Pozniak, A., Gazzard, B.
(2004). A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). J Antimicrob Chemother
53: 501-505
[Abstract][Full Text]
